Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-063518
Filing Date
2025-05-05
Accepted
2025-05-05 16:04:25
Documents
68
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q sndx-20250331.htm   iXBRL 10-Q 1638662
2 EX-31.1 sndx-ex31_1.htm EX-31.1 15053
3 EX-31.2 sndx-ex31_2.htm EX-31.2 15613
4 EX-32.1 sndx-ex32_1.htm EX-32.1 14809
  Complete submission text file 0000950170-25-063518.txt   7409594

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT sndx-20250331.xsd EX-101.SCH 1225146
70 EXTRACTED XBRL INSTANCE DOCUMENT sndx-20250331_htm.xml XML 1206104
Mailing Address 730 THIRD AVENUE 9TH FLOOR NEW YORK NY 10017
Business Address 730 THIRD AVENUE 9TH FLOOR NEW YORK NY 10017 781-419-1400
Syndax Pharmaceuticals Inc (Filer) CIK: 0001395937 (see all company filings)

EIN.: 320162505 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37708 | Film No.: 25912832
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)